Astellas Farma Portugal is an affiliate of Astellas Pharma Inc., based in Tokyo, and globally one of the companies most focused on the investigation of innovative pharmaceutical products.
Research and Development are at the center of everything we do, and this not only drives our work today, but also stimulates what we will do tomorrow, allowing us to develop new medicines with the potential to help millions of people. That is why we are focused on transforming innovative science into value for patients, in areas with unmet medical needs, in which we have experience and where we believe that innovation can help answer some of these most significant needs.
The focus areas are constantly adapting, in order to respond to advances in science and changes in disease treatment paradigms. Given the major changes in the health sector environment, we realize that identifying medicines discovery opportunities in a more flexible and efficient way is crucial for our development, as well as for creating value for patients. Our approach is not fixed, it evolves continuously adapting its components to reflect the progress of research and development and the latest advances in science and technology. This allows Astellas to develop its strengths while identifying and realizing new medicines discovery opportunities in a flexible and efficient way.
, 
Every day we engage in priority therapeutic areas, such as Oncology, Urology, Transplantation and Hematology. Our greatest commitment is to give patients hope for a better future and that is why our “Raison d’Être” is to contribute to improving the health of people around the world, by providing innovative and reliable medicines.
With the mission of sustained growth in the company’s value, Astellas will seek to be the company of choice among all its stakeholders, including its customers, shareholders, employees, and the global community.
We excel in investing in conscious innovation, which brings clear advantages for the treatment of patients. We have a pipeline of innovative medicines under development, aimed at areas with limited therapeutic options, such as Anemia in Chronic Kidney Disease, and Acute Myeloid Leukemia (AML).
An open and innovative mindset is the key to our success and taking care of our health and well-being is our priority. Our focus remains on the successful launch of new products and expanding the reach of our current portfolio. It is in this way that we promise to fulfill our obligations to all stakeholders, acting ethically and actively seeking to disclose information. At the forefront turning innovative science into value for patients.
